Silvia Novello

48.2k total citations · 10 hit papers
466 papers, 19.1k citations indexed

About

Silvia Novello is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Silvia Novello has authored 466 papers receiving a total of 19.1k indexed citations (citations by other indexed papers that have themselves been cited), including 379 papers in Pulmonary and Respiratory Medicine, 311 papers in Oncology and 80 papers in Molecular Biology. Recurrent topics in Silvia Novello's work include Lung Cancer Treatments and Mutations (323 papers), Lung Cancer Research Studies (152 papers) and Lung Cancer Diagnosis and Treatment (129 papers). Silvia Novello is often cited by papers focused on Lung Cancer Treatments and Mutations (323 papers), Lung Cancer Research Studies (152 papers) and Lung Cancer Diagnosis and Treatment (129 papers). Silvia Novello collaborates with scholars based in Italy, United States and France. Silvia Novello's co-authors include Giorgio V. Scagliotti, Martin Reck, Sanjay Popat, Solange Peters, Keith M. Kerr, Tony Mok, Fabrice Barlési, Matteo Giaj Levra, David Planchard and Giovanni Selvaggi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Silvia Novello

456 papers receiving 18.8k citations

Hit Papers

Metastatic non-small-cell lung cancer: ESMO... 2006 2026 2012 2019 2016 2018 2014 2016 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2016 1.9k citations Silvia Novello, Fabrice Barlési et al. profile →
  2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2018 1.6k citations David Planchard, Sanjay Popat et al. profile →
  3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
    2014 694 citations Martin Reck, José Barrueco et al. The Lancet Oncology profile →
  4. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
    2016 612 citations David Planchard, Benjamin Besse et al. The Lancet Oncology profile →
  5. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    2006 505 citations Silvia Novello, P. Borasio et al. profile →
  6. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
  7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
    2017 412 citations Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology profile →
  8. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →
  9. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
    2023 233 citations Silvia Novello et al. Journal of Clinical Oncology profile →
  10. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    2021 201 citations Margarita Majem, Silvia Novello et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silvia Novello Italy 61 13.0k 11.6k 5.0k 3.6k 1.5k 466 19.1k
Benjamin Solomon Australia 61 14.1k 1.1× 12.7k 1.1× 6.7k 1.3× 4.3k 1.2× 1.5k 1.0× 415 20.8k
Yuichiro Ohe Japan 61 14.9k 1.2× 14.4k 1.2× 5.9k 1.2× 3.9k 1.1× 1.3k 0.9× 561 21.9k
Julian R. Molina United States 44 8.2k 0.6× 10.5k 0.9× 6.2k 1.3× 3.3k 0.9× 1.4k 0.9× 216 18.3k
Primo N. Lara United States 60 8.5k 0.7× 7.0k 0.6× 6.0k 1.2× 3.5k 1.0× 1.5k 1.0× 458 16.3k
Benjamin Besse France 64 10.4k 0.8× 12.2k 1.1× 5.6k 1.1× 3.8k 1.0× 971 0.6× 708 18.8k
Jacek Jassem Poland 59 8.0k 0.6× 11.4k 1.0× 4.8k 1.0× 3.9k 1.1× 3.3k 2.1× 523 19.9k
Lucio Crinò Italy 67 13.4k 1.0× 13.5k 1.2× 5.5k 1.1× 3.3k 0.9× 1.3k 0.8× 372 19.4k
Heather A. Wakelee United States 60 7.5k 0.6× 6.9k 0.6× 3.9k 0.8× 4.0k 1.1× 852 0.6× 447 13.5k
Keyue Ding Canada 45 8.4k 0.6× 8.1k 0.7× 3.4k 0.7× 2.6k 0.7× 1.7k 1.1× 218 14.5k
Nobuyuki Yamamoto Japan 58 12.5k 1.0× 11.6k 1.0× 4.0k 0.8× 2.5k 0.7× 1.2k 0.8× 574 17.3k

Countries citing papers authored by Silvia Novello

Since Specialization
Citations

This map shows the geographic impact of Silvia Novello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Novello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Novello more than expected).

Fields of papers citing papers by Silvia Novello

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Novello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Novello. The network helps show where Silvia Novello may publish in the future.

Co-authorship network of co-authors of Silvia Novello

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Novello. A scholar is included among the top collaborators of Silvia Novello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Novello. Silvia Novello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations
2.
Olivero, Martina, Riccardo Taulli, Francesca Bersani, et al.. (2025). Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression. International Journal of Molecular Sciences. 26(13). 6353–6353. 2 indexed citations
3.
Jänne, Pasi A., Toshio Kubo, Kiichiro Ninomiya, et al.. (2024). Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8543–8543. 4 indexed citations
4.
Malapelle, Umberto, Fabio Pagni, Filippo Fraggetta, et al.. (2023). Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group. Critical Reviews in Oncology/Hematology. 193. 104217–104217. 7 indexed citations
5.
Bertaglia, Valentina, Anna Morelli, Cinzia Solinas, et al.. (2023). Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Critical Reviews in Oncology/Hematology. 184. 103954–103954. 11 indexed citations
6.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
7.
Tagliamento, Marco, Massimo Di Maïo, Jordi Remón, et al.. (2023). Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(1). 166–172. 8 indexed citations
8.
Bironzo, Paolo, Luca Primo, Silvia Novello, et al.. (2022). Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response. Clinical Lung Cancer. 23(6). e347–e352. 7 indexed citations
9.
Wheeler, Eleanor, Suzanne Wait, Tit Albreht, et al.. (2022). The need for a comprehensive and integrated approach to lung cancer policy in Europe. European Journal of Cancer. 175. 54–59. 3 indexed citations
10.
Tagliamento, Marco, Jordi Remón, Matteo Giaj Levra, et al.. (2022). Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey. JTO Clinical and Research Reports. 4(1). 100446–100446. 3 indexed citations
11.
Perrone, Fabiana, Lorenzo Belluomini, Marco Mazzotta, et al.. (2021). Exploring the role of respiratory microbiome in lung cancer: A systematic review. Critical Reviews in Oncology/Hematology. 164. 103404–103404. 24 indexed citations
12.
Remón, Jordi, Nicolas Girard, Silvia Novello, et al.. (2021). PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer. 23(3). e243–e246. 24 indexed citations
13.
Passaro, Antonio, Silvia Novello, Diana Giannarelli, et al.. (2021). Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers. 13(12). 2935–2935. 14 indexed citations
14.
Lombardi, Pasquale, Laura Marandino, Emmanuele De Luca, et al.. (2020). Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. Critical Reviews in Oncology/Hematology. 146. 102877–102877. 18 indexed citations
15.
Mariniello, Annapaola, Silvia Novello, Giorgio V. Scagliotti, & Suresh S. Ramalingam. (2020). Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology. 152. 102980–102980. 11 indexed citations
16.
Shaw, Alice T., Tae Min Kim, Lucio Crinò, et al.. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 18(7). 874–886. 412 indexed citations breakdown →
17.
Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations
18.
Riganti, Chiara, Iris C. Salaroglio, Chiara Falcomatà, et al.. (2017). Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. OncoImmunology. 7(3). e1398874–e1398874. 34 indexed citations
19.
Ceppi, Paolo, Mauro Papotti, Valentina Monica, et al.. (2009). Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin. Molecular Cancer Therapeutics. 8(11). 3066–3074. 51 indexed citations
20.
Saviozzi, Silvia, Paolo Ceppi, Silvia Novello, et al.. (2009). Non–Small Cell Lung Cancer Exhibits Transcript Overexpression of Genes Associated with Homologous Recombination and DNA Replication Pathways. Cancer Research. 69(8). 3390–3396. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benjamin Solomon Breakdown of academic impact, for papers by Yuichiro Ohe Breakdown of academic impact, for papers by Julian R. Molina Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Lucio Crinò Breakdown of academic impact, for papers by Heather A. Wakelee Breakdown of academic impact, for papers by Keyue Ding Breakdown of academic impact, for papers by Nobuyuki Yamamoto
Rankless by CCL
2026